Clinical trials
Phase 2 Psoriasis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
138 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 5 |
| 2004 | 2 |
| 2005 | 7 |
| 2006 | 4 |
| 2007 | 7 |
| 2008 | 10 |
| 2009 | 7 |
| 2010 | 8 |
| 2011 | 6 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 7 |
| 2016 | 11 |
| 2017 | 5 |
| 2018 | 6 |
| 2019 | 10 |
| 2020 | 5 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 116 |
| Terminated | 14 |
| Recruiting | 3 |
| Suspended | 2 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 8 |
| Boehringer Ingelheim | 7 |
| Amgen | 4 |
| Bausch Health Americas, Inc. | 4 |
| Novartis Pharmaceuticals | 4 |
| UCB Biopharma SRL | 4 |
| Astellas Pharma Inc | 3 |
| Bristol-Myers Squibb | 3 |
| Eli Lilly and Company | 3 |
| Galderma R&D | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Psoriasis | 138 |
| Skin Diseases | 12 |
| Arthritis, Psoriatic | 6 |
| Plaque, Amyloid | 6 |
| Lymphoma, Follicular | 5 |
| Pruritus | 4 |
| Arthritis | 3 |
| Dermatitis, Atopic | 3 |
| Inflammation | 3 |
| Autoimmune Diseases | 2 |
Trials
Showing 1 to 25 of 138. Each trial links to its page on Pharma Observatory.
38 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.